Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc. (Delaware)

Grade Last Price % Change Price Change
grade D 0.2359 2.57% 0.01
ATNM closed up 2.57 percent on Friday, September 13, 2019, on 44 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***
6 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ATNM trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Doji - Bearish? Reversal 0.00%
50 DMA Resistance Bearish 2.57%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.57%
NR7 Range Contraction 2.57%
50 DMA Resistance Bearish 2.57%
20 DMA Support Bullish 2.57%
MACD Bullish Signal Line Cross Bullish 2.57%
Up 3 Days in a Row Strength 2.57%
Crossed Above 20 DMA Bullish 3.92%

Older signals for ATNM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
ATNM Chart by TradingView
Basic chart:
Profile
Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Chemistry Biopharmaceutical Cancer Physical Sciences Natural Sciences Immunology Chemical Elements Antibodies Stem Cells Acute Myeloid Leukemia Monoclonal Antibody Transplantation Platform Technology Actinides
Is ATNM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 8 Sell-siders trim views on Inogen after Q2 miss and guidance cut
Aug 6 The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
Jul 23 Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B
Jul 17 How Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Can Impact Your Portfolio Volatility
Jul 11 Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers
Jun 26 Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 25 Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 20 Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 14 The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA
Jun 4 Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting
See more ATNM news...
Indicators
Indicator Value
52 Week High 0.865
52 Week Low 0.19
Average Volume 705,368
200-Day Moving Average 0.3803
50-Day Moving Average 0.2317
20-Day Moving Average 0.227
10-Day Moving Average 0.2252
Average True Range 0.018
ADX 9.86
+DI 15.8317
-DI 11.7836
Chandelier Exit (Long, 3 ATRs ) 0.206
Chandelier Exit (Short, 3 ATRs ) 0.244
Upper Bollinger Band 0.2507
Lower Bollinger Band 0.2033
Percent B (%b) 0.69
BandWidth 20.881057
MACD Line -0.0011
MACD Signal Line -0.0025
MACD Histogram 0.0015
Fundamentals Value
Market Cap 18.88 Million
Num Shares 80 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.25
Resistance 3 (R3) 0.25 0.25 0.25
Resistance 2 (R2) 0.25 0.24 0.25 0.25
Resistance 1 (R1) 0.24 0.24 0.24 0.24 0.25
Pivot Point 0.24 0.24 0.24 0.24 0.24
Support 1 (S1) 0.23 0.23 0.23 0.23 0.23
Support 2 (S2) 0.23 0.23 0.23 0.22
Support 3 (S3) 0.22 0.23 0.22
Support 4 (S4) 0.22